Tianjin Pharmaceutical Da Ren Tang Group Valuation

Q: What is the Fair Price of 600329 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600329 (CN¥34.99) is trading above our estimate of [[fair value]] (CN¥3.32)

Is 600329 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600329 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600329 (CN¥34.99) is trading above our estimate of fair value (CN¥3.32)

Significantly Below Fair Value: 600329 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600329?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 600329. This is calculated by dividing 600329's market cap by their current preferred multiple.
What is 600329's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥22.85b

600329 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.6x
Enterprise Value/EBITDA	22.3x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does 600329's PE Ratio compare to its peers?

The above table shows the PE ratio for 600329 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.5x
600380 Joincare Pharmaceutical Group IndustryLtd	16x	11.8%	CN¥22.7b
600521 Zhejiang Huahai Pharmaceutical	26.6x	24.2%	CN¥24.7b
600062 China Resources Double-Crane PharmaceuticalLtd	16.2x	11.1%	CN¥22.2b
002262 Jiangsu Nhwa Pharmaceutical	23.4x	19.5%	CN¥25.2b
600329 Tianjin Pharmaceutical Da Ren Tang Group	27.7x	19.2%	CN¥22.8b

Price-To-Earnings vs Peers: 600329 is expensive based on its Price-To-Earnings Ratio (27.7x) compared to the peer average (20.5x).

Price to Earnings Ratio vs Industry

How does 600329's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.6%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 600329 is good value based on its Price-To-Earnings Ratio (27.7x) compared to the CN Pharmaceuticals industry average (31.3x).

Price to Earnings Ratio vs Fair Ratio

What is 600329's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600329 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	27.7x
Fair PE Ratio	29.9x

Price-To-Earnings vs Fair Ratio: 600329 is good value based on its Price-To-Earnings Ratio (27.7x) compared to the estimated Fair Price-To-Earnings Ratio (29.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.